Bristol-Myers Squibb Stock
Bristol-Myers Squibb Stock
Pros and Cons of Bristol-Myers Squibb in the next few years
Pros
Cons
Performance of Bristol-Myers Squibb vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Bristol-Myers Squibb | -1.740% | 0.780% | -1.248% | -20.000% | -5.345% | -15.991% | -3.121% |
Johnson & Johnson | -1.200% | -0.713% | 2.570% | -2.778% | 4.294% | 5.170% | 25.429% |
Elanco Animal Health Inc. | -1.330% | 2.475% | 1.048% | 21.604% | -0.163% | -51.147% | - |
Biogen Inc. | 1.070% | 0.979% | -2.932% | -24.938% | -23.473% | -29.470% | -15.421% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.When evaluating the financials of Bristol-Myers Squibb Company (symbol: BMY), the impression is that the company embodies a complex but compelling pharmaceutical player characterized by both strengths and challenges. While the balance sheets, cash flow statements, and income statements showcase a robust revenue-generating ability, several underlying factors such as profitability ratios and market performance warrant further scrutiny.
In order to provide clarity on Bristol-Myers’ financial health, it is necessary to explore the various pros and cons that define its current financial position.
*Pros: *
Comments